CA3124872A1 - Tasimelteon for regulating melatonin production - Google Patents

Tasimelteon for regulating melatonin production

Info

Publication number
CA3124872A1
CA3124872A1 CA3124872A CA3124872A CA3124872A1 CA 3124872 A1 CA3124872 A1 CA 3124872A1 CA 3124872 A CA3124872 A CA 3124872A CA 3124872 A CA3124872 A CA 3124872A CA 3124872 A1 CA3124872 A1 CA 3124872A1
Authority
CA
Canada
Prior art keywords
tasimelteon
individual
melatonin
administration
sleep
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3124872A
Other languages
English (en)
French (fr)
Inventor
Christian Lavedan
Mihael H. Polymeropoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanda Pharmaceuticals Inc
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54147267&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3124872(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of CA3124872A1 publication Critical patent/CA3124872A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Electric Connection Of Electric Components To Printed Circuits (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Processing Of Solid Wastes (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Led Device Packages (AREA)
  • Saccharide Compounds (AREA)
  • Coils Or Transformers For Communication (AREA)
  • Indole Compounds (AREA)
CA3124872A 2014-09-02 2015-08-29 Tasimelteon for regulating melatonin production Pending CA3124872A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462044856P 2014-09-02 2014-09-02
US62/044,856 2014-09-02
US201562169635P 2015-06-02 2015-06-02
US62/169,635 2015-06-02
CA2957588A CA2957588C (en) 2014-09-02 2015-08-29 Tasimelteon for treating smith-magenis syndrome

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2957588A Division CA2957588C (en) 2014-09-02 2015-08-29 Tasimelteon for treating smith-magenis syndrome

Publications (1)

Publication Number Publication Date
CA3124872A1 true CA3124872A1 (en) 2016-03-10

Family

ID=54147267

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3124872A Pending CA3124872A1 (en) 2014-09-02 2015-08-29 Tasimelteon for regulating melatonin production
CA2957588A Active CA2957588C (en) 2014-09-02 2015-08-29 Tasimelteon for treating smith-magenis syndrome

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2957588A Active CA2957588C (en) 2014-09-02 2015-08-29 Tasimelteon for treating smith-magenis syndrome

Country Status (17)

Country Link
US (5) US10179119B2 (enExample)
EP (2) EP3188727B1 (enExample)
JP (3) JP6903571B2 (enExample)
KR (2) KR20170048541A (enExample)
CN (2) CN106604726A (enExample)
AU (2) AU2015312252B2 (enExample)
BR (1) BR112017003644A2 (enExample)
CA (2) CA3124872A1 (enExample)
DK (1) DK3188727T3 (enExample)
ES (1) ES2936833T3 (enExample)
FI (1) FI3188727T3 (enExample)
HR (1) HRP20230070T1 (enExample)
HU (1) HUE061051T2 (enExample)
MX (1) MX386150B (enExample)
PT (1) PT3188727T (enExample)
SI (1) SI3188727T1 (enExample)
WO (1) WO2016036619A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101587394B1 (ko) * 2006-05-22 2016-01-21 반다 파마슈티칼즈, 인코퍼레이티드. 멜라토닌 효능제 치료
CN106604726A (zh) * 2014-09-02 2017-04-26 万达制药公司 用于治疗史密斯‑马吉利综合征的他司美琼
EP3761974A1 (en) * 2018-03-04 2021-01-13 Vanda Pharmaceuticals Inc. Treatment of disorders with tasimelteon
JP2022500420A (ja) * 2018-09-12 2022-01-04 バンダ・ファーマシューティカルズ・インコーポレイテッドVanda Pharmaceuticals Inc. 睡眠又は睡眠後パフォーマンスの改善
NZ811397A (en) 2019-12-13 2025-11-28 Vanda Pharmaceuticals Inc Liquid tasimelteon formulations and methods of use thereof
US20230314471A1 (en) 2020-08-27 2023-10-05 Yokowo Co., Ltd. Inspection device
AU2022345260A1 (en) * 2021-09-14 2024-04-04 Vanda Pharmaceuticals Inc. Treatment of sleep disturbances in autism spectrum disorder patients

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100499106B1 (ko) 1996-12-10 2005-07-01 브리스톨-마이어즈 스퀴브 컴페니 벤조디옥솔, 벤조퓨란, 디히드로벤조퓨란, 및 벤조디옥산 멜라토닌 작용제
US20050137247A1 (en) 2003-12-22 2005-06-23 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
US7754902B2 (en) 2006-05-18 2010-07-13 Vanda Pharmaceuticals, Inc. Ruthenium(II) catalysts for use in stereoselective cyclopropanations
KR101587394B1 (ko) 2006-05-22 2016-01-21 반다 파마슈티칼즈, 인코퍼레이티드. 멜라토닌 효능제 치료
US20080260837A1 (en) 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
KR100928515B1 (ko) 2008-04-02 2009-11-26 주식회사 동부하이텍 데이터 수신 장치
WO2011009102A1 (en) 2009-07-16 2011-01-20 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
IL330095A (en) * 2012-01-26 2026-08-01 Vanda Pharmaceuticals Inc Tesimalta for use in the treatment of asynchronous circadian rhythm of cortisol
CN102675268A (zh) * 2012-05-18 2012-09-19 济南志合医药科技有限公司 制备（1r，2r）-2-（2,3-二氢苯并呋喃-4-基）环丙甲胺的方法
US10376487B2 (en) * 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
CN106604726A (zh) 2014-09-02 2017-04-26 万达制药公司 用于治疗史密斯‑马吉利综合征的他司美琼
NZ811397A (en) * 2019-12-13 2025-11-28 Vanda Pharmaceuticals Inc Liquid tasimelteon formulations and methods of use thereof

Also Published As

Publication number Publication date
JP7252390B2 (ja) 2023-04-04
US20190105297A1 (en) 2019-04-11
EP4137129A1 (en) 2023-02-22
KR20170048541A (ko) 2017-05-08
ES2936833T3 (es) 2023-03-22
EP3188727B1 (en) 2022-11-09
US20170239210A1 (en) 2017-08-24
JP2022078291A (ja) 2022-05-24
SI3188727T1 (sl) 2023-03-31
NZ729901A (en) 2020-09-25
CN116098887A (zh) 2023-05-12
JP6903571B2 (ja) 2021-07-14
AU2020239640A1 (en) 2020-10-15
US20240293355A1 (en) 2024-09-05
JP2017526693A (ja) 2017-09-14
DK3188727T3 (da) 2023-02-06
US20200237712A1 (en) 2020-07-30
CA2957588A1 (en) 2016-03-10
US20220133681A1 (en) 2022-05-05
US10653665B2 (en) 2020-05-19
AU2015312252B2 (en) 2020-07-02
KR20240015729A (ko) 2024-02-05
WO2016036619A1 (en) 2016-03-10
HUE061051T2 (hu) 2023-05-28
CN106604726A (zh) 2017-04-26
MX386150B (es) 2025-03-18
AU2020239640B2 (en) 2020-11-05
JP7132277B2 (ja) 2022-09-06
CA2957588C (en) 2021-08-31
BR112017003644A2 (pt) 2017-11-28
PT3188727T (pt) 2023-01-30
US10179119B2 (en) 2019-01-15
NZ765911A (en) 2023-08-25
FI3188727T3 (fi) 2023-02-20
HRP20230070T1 (hr) 2023-03-17
JP2020143159A (ja) 2020-09-10
US11266622B2 (en) 2022-03-08
MX2017002796A (es) 2017-06-09
AU2015312252A1 (en) 2017-03-30
EP3188727A1 (en) 2017-07-12

Similar Documents

Publication Publication Date Title
AU2020239640B2 (en) Tasimelteon for treating smith-magenis syndrome
Yukuhiro et al. Effects of ramelteon (TAK-375) on nocturnal sleep in freely moving monkeys
BR112019020798A2 (pt) métodos e composições para tratamento de danos associados ao envelhecimento usando inibidores de ccr3
CN104519877A (zh) 昼夜节律紊乱的治疗
CA2949910C (en) Modulators of intracellular chloride concentration for treating neurodegenerative diseases with parkinsonian syndromes
AU2018297653B2 (en) New uses of a pure 5-HT6 receptor antagonist
CN112367998B (zh) 用组胺-3受体反向激动剂进行治疗的方法
JP2019516696A (ja) 純粋な５−ｈｔ６受容体アンタゴニストのｎｍｄａ受容体アンタゴニストとの組合せ
NZ729901B2 (en) Tasimelteon for treating smith-magenis syndrome
NZ765911B2 (en) Tasimelteon for treating smith-magenis syndrome
EA036480B1 (ru) Тройная комбинация обратных агонистов рецептора гистамина-3, ингибитора ацетилхолинэстеразы и антагониста рецептора nmda
EP3607948A1 (en) Tissue transglutaminase modulators for medicinal use
KR20220110518A (ko) 치매 환자의 행동 및 심리적 증상 치료
AU2009292498A1 (en) Novel pharmaceutical composition for treatment of nociceptive pain

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210719